Company: STAA
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058174
Chunk: 8

Company: STAAR SURGICAL CO
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 8
---
 to our Board. Experience.  Mr. Farrell was appointed Chief Executive Officer of STAAR in February 2025. He joined STAAR in 2016 as a member of the Board of Directors, and he served as Lead Independent Director from December 2023 to February 2025. From February 2024 to February 2025, Mr. Farrell was a consultant to private companies focused on improving financial performance and operating efficiencies. From February 2011 to February 2024, Mr. Farrell served as the Chief Executive Officer and a member of the Board of Directors of Convey Health Solutions, a technology-enabled healthcare business process outsourcer. Also, from 2012 to 2020, he was a member of the Board of Directors of Lineage Cell Therapeutics, formerly known as BioTime, Inc., a clinical stage biotechnology company focused in the field of regenerative medicine. From 2008 to 2009, Mr. Farrell served as the Executive Vice President and Chief Financial Officer for Stream Global Services, a private equity owned business process outsourcer. From 1999 to 2007, Mr. Farrell served in multiple executive roles, including Chief Financial Officer, Chief Operating |                                                                                                 |

| 2025 Proxy Statement | – 5 – |

#### ––Information Regarding Director Nominees––
| Officer, and President, at PolyMedica Corporation (NASDAQ: PLMD), a provider of diabetes supplies that was acquired by Medco Health Solutions in 2007. From 2007 to 2014, he served as a member of the Board of Questcor Pharmaceuticals (NASDAQ: QCOR), a biopharmaceutical company that was acquired by Mallinckrodt PLC in 2014. Mr. Farrell spent five years as a Senior Manager at PricewaterhouseCoopers from 1994 to 1999, and was a Certified Public Accountant (CPA).  Education.  Mr. Farrell earned a B.A. from Harvard University and an M.B.A. at the University of Virginia, Darden School of Business. |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Wei JiangDirector since March 2024Age 61 |
| Qualifications. The Board concluded that Mr. Jiang should serve as a directior because of his more than 25 years’ experience in the pharmaceutical and medical device industries, with particular focus in China and the Asia Pacific region. In addition, the Board believes that it can benefit from Mr. Jiang’s other